Dr. Buss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Beth Israel Deaconess Medical Center Yamins 109
Boston, MA 02215Phone+1 617-667-7467Fax+1 617-667-2854
Summary
- Dr. Mary Buss is a palliative care physician and medical oncologist in Boston, MA. She graduated from Williams College with a degree in Bio-Medical Ethics and received her medical degree from Georgetown University School of Medicine. After residency at the University of Pittsburgh, she came to Beth Israel Deaconess Medical Center for fellowship training. As faculty there, she started the outpatient palliative care practice and the Palliative Medicine fellowship. In 2022, she joined Tufts Medical Center to expand their palliative care clinical practice and educational footprint. She has expertise in pain and symptom management and communication skills training. Her scholarly work focuses on developing models to enhance delivery and integration of palliative care.
Education & Training
- Harvard School of Public HealthMPH, Clinical Effectiveness, 2003 - 2007
- Massachusetts General Hospital/Dana-Farber Cancer Institute/Children's Hospital BostonFellowship, Hospice and Palliative Medicine, 2003 - 2004
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
- UPMC Medical EducationResidency, Internal Medicine, 1997 - 2000
- Georgetown University School of MedicineClass of 1997
- Williams CollegeBA, Bio-Medical Ethics, Cum Laude, 1989 - 1993
Certifications & Licensure
- MA State Medical License 2001 - 2026
- CT State Medical License 2024 - 2025
- PA State Medical License 1998 - 2002
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Cunniff-Dixon Physician Award The Hastings Center, 2015
Clinical Trials
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer Start of enrollment: 2016 Nov 14
Publications & Presentations
PubMed
- 87 citationsUnderstanding patients' attitudes toward communication about the cost of cancer care.Andrea J. Bullock, Erin Hofstatter, Melinda L. Yushak, Mary K. Buss
Journal of Oncology Practice. 2012-02-28 - 430 citationsCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyJoyce F. Liu, William T. Barry, Michael J. Birrer, Jung-Min Lee, Ronald J. Buckanovich
The Lancet. Oncology. 2014-10-01 - 164 citationsOlaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen Cadoo
The Lancet. Oncology. 2019-04-01
Press Mentions
- ‘Curiosity Is the Cure': Local Experts Discuss Hurdles Facing Cannabis in Health CareMarch 27th, 2023
- Moral Distress in NeurosurgeryAugust 15th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: